Kvartalsrapport Q1 2023

===== SIDA 1 =====

Block listing Interim Review
1 June 2023 15:05 BST
BLOCK LISTING SIX MONTHLY RETURN
I
NFORMATION
 
PROVIDED
 
ON
 
THIS
 
FORM
 
MUST
 
BE
 
TYPED
 
OR
 
PRINTED
 
ELECTRONICALLY
 
AND
 
PROVIDED
 
TO
 
AN
 
RIS
.
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
Date
: 
1 June 2023
Name of 
applicant
:
ASTRAZENECA PLC
 
Name of scheme:
ASTRAZENECA SHARE OPTION PLAN;
ASTRAZENECA SAVINGS-
RELATED
 SHARE OPTION PLAN;
ASTRAZENECA ALL-EMPLOYEE SHARE
PLAN; ASTRAZENECA PLC 2012
SAVINGS-RELATED SHARE OPTION
SCHEME
 
Period of return:
From:
1 DECEMBER
2022
To:
31 MAY 2023
 
Balance of unallotted securities under scheme(s)
from previous return:
4,818,134
 
Plus:
 
The amount by which the block scheme(s)
has been increased since the date of the last
return (if any increase has been applied for):
0
 
Less:
 
Number of 
securities
 issued/allotted under
scheme(s) during period (see LR3.5.7G):
341,752
 
Equals:
 
Balance under scheme(s) not yet
issued/allotted at end of period:
4,476,382
 
Name of contact:
Hannah Tattersall
 
Telephone number of contact:
+44 (0)746 498 2582
 
AstraZeneca
AstraZeneca
 
(LSE/STO/Nasdaq:
 
AZN)
 
is
 
a
 
global,
 
science-led
 
biopharmaceutical
 
company
that
 
focuses
 
on
 
the
 
discovery,
 
development,
 
and
 
commercialisation
 
of
 
prescription
 
medicines
 
in
Oncology,
 
Rare
 
Diseases,
 
and
 
BioPharmaceuticals,
 
including
 
Cardiovascular,
 
Renal
 
&
Metabolism,
 
and
 
Respiratory
 
&
 
Immunology.
 
Based
 
in
 
Cambridge,
 
UK,
 
AstraZeneca
 
operates
in
 
over
 
100
 
countries
 
and
 
its
 
innovative
 
medicines
 
are
 
used
 
by
 
millions
 
of
 
patients
 
worldwide.
Please visit 
astrazeneca.com
 and follow the Company on Twitter 
@AstraZeneca
.
Contacts
For
 
details
 
on
 
how
 
to
 
contact
 
the
 
Investor
 
Relations
 
Team,
 
please
 
click
 
here
.
 
For
 
Media
contacts, click 
here
.
Adrian Kemp
Company Secretary
AstraZeneca PLC

===== SIDA 2 =====

This information is provided by RNS, the news service of the London Stock Exchange. RNS is
approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information
may apply. For further information, please contact 
rns@lseg.com
 or visit 
www.rns.com
.